Table of Contents
Hepatitis Research and Treatment
Volume 2014 (2014), Article ID 373212, 7 pages
Research Article

Hepatitis B Vaccination and Screening Awareness in Primary Care Practitioners

1Division of Gastroenterology and Hepatology, University of Wisconsin School of Medicine and Public Health and William S. Middleton VAMC, Madison, WI 53705, USA
2Division of Gastroenterology and Hepatology, Oregon Health Sciences University and Portland VAMC, Portland, OR 97239, USA

Received 4 June 2013; Accepted 10 January 2014; Published 6 March 2014

Academic Editor: Annagiulia Gramenzi

Copyright © 2014 Adnan Said and Janice H. Jou. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. The goals of Healthy People US 2020 have called for increased screening and vaccination of high-risk groups for Hepatitis B (HBV). Methods. We performed a survey of 400 randomly chosen primary care practitioners (PCPs) in Wisconsin to assess their knowledge, attitudes, and practices regarding screening and vaccination for HBV. Results. Screening rates of patients at risk of sexual transmission were low, with 61% of respondents stating that they screen patients who had more than 1 sex partner in 6 months and 86% screening patients with a history of sex with prostitutes. Screening rate for persons with a history of intravenous drug use was 94%. Children of immigrants were screened by 65%, persons on hemodialysis by 73%, and prison inmates by 69%. Screening increased with provider experience with HBV. Deficiencies in vaccination rates mirrored screening practices. Major barriers to screening were cost, someone else’s responsibility, time constraints, or lack of knowledge. Conclusions. Without improved education and practices of PCPs about HBV screening and vaccination, the goals of healthy people 2020 regarding HBV will not be met. Barriers to screening and vaccination need to be addressed. Cost-effectiveness of alternative strategies such as universal vaccination under the age of 50 should be explored.